Previous 10 | Next 10 |
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement wit...
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will rep...
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster prese...
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointmen...
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company m...
2023-03-07 10:35:21 ET Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Conference Call March 7, 2023 08:30 AM ET Company Participants Danielle Dudgeon - Stern IR Kevin Boyle Senior - CEO Drew Deniger - VP, Research and Development Abhi Srivastava - VP, Tec...
2023-03-07 07:03:53 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q4 GAAP EPS of -$0.04 beats by $0.03 . As of December 31, 2022, Alaunos had approximately $53.0 million in cash balances, which includes restricted cash of approximately $13.9 million. Base...
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enr...
2023-03-06 11:10:18 ET Alaunos Therapeutics ( NASDAQ: TCRT ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before markets open. The consensus EPS Estimate is -$0.07 (-40.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 1 year, TCRT ...
2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Alaunos Therapeutics Inc. Website:
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...